Morphotek to Present Three Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting 2017

News provided by

Mar 28, 2017, 10:00 ET

EXTON, Pa., March 28, 2017 /PRNewswire/ -- Morphotek^®, Inc., a subsidiary of Eisai Inc., announced today that it will present three posters at the Annual Meeting of the American Association for Cancer Research (AACR) in Washington, D.C. being held April 1-5, 2017. Highlighted among the posters will be new preclinical data on Morphotek's proprietary antibody-drug conjugate (ADC) technology, REsidue-SPEcific Conjugation Technology^TM (RESPECT^TM), along with the immunosuppressive effects of CA125 on immune-mediated therapeutic antibodies.

Title

Abstract/Poster No.

Poster Presentation

(All times are U.S. ET)

RESPECT (REsidue-SPEcific Conjugation Technology): A Platform Technology Utilizing Native Cysteine and Lysine Residues for the Generation of Homogeneous Antibody-Drug Conjugates

Abstract: 65

Poster Board: 16

Session Category: Experimental and

Molecular Therapeutics

Session Title: Antibody Technology

Date: Sunday, April 2, 2017

Time: 1:00 p.m. to 5:00 p.m.

Location: Halls A-C; Poster Section 3

CA125/MUC16 suppresses antibody-dependent cellular cytotoxicity of IgG1-based therapies via perturbation of antibody Fc-Receptor engagement on immune effector cells

Abstract: 644

Poster Board: 18

Session Category: Immunology

Session Title: Tumor Antigens and

Adaptive Immunity

Date: Sunday, April 2, 2017

Time: 1:00 p.m. to 5:00 p.m.

Location: Halls A-C; Poster Section 27

Comprehensive genomic characterization of a large cohort of platinum sensitive high grade serous ovarian cancer (HGSOC) FFPE specimens

Abstract: 1743

Poster Board: 3

Session Category: Clinical Research

Session Title: Molecular Classification

of Tumors

Date: Monday, April 3, 2017

Time: 8:00 a.m. to 12:00 p.m.

Location: Halls A-C; Poster Section 31

To learn more about Morphotek and its proprietary ADC technology and services, please visit us at booth 2066 at the AACR Annual Meeting.

About Morphotek

Morphotek^®, Inc., a subsidiary of Eisai Inc., is a clinical-stage biotechnology company focused on developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases. Our mission is to develop novel, targeted therapies that attack underlying disease pathways and overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. Our diverse pipeline includes clinical-stage monoclonal antibodies to lead targets folate receptor alpha, mesothelin and endosialin, as well as antibody drug conjugates and bispecific antibodies to undisclosed targets in preclinical development. Our mission is supported by the proprietary cutting-edge technologies in antibody engineering, manufacturing and screening optimization platforms, along with our expertise in developing diagnostics to support patient selection and therapeutic strategy. For more information, please visit www.morphotek.com.

About Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.